Role of melatonin for prevention of necrotizing enterocolitis in preterm infants: a randomized controlled trial.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Feeding intolerance (FI) in preterm infants may signal necrotizing enterocolitis (NEC), in which oxidative stress (OS) plays a central role. Melatonin has demonstrated promise in mitigating neonatal OS-related diseases. The study is aimed to assess the effect of enteral melatonin on the progression of FI symptoms, NEC incidence, and tumor necrosis factor-alpha (TNF-α) levels in preterm neonates with FI, compared with conventional therapy (CT). Ninety preterm neonates with FI were randomly assigned to either the melatonin group (MT, n = 45), who received melatonin plus conventional therapy, or the conventional group (CT, n = 45), who received conventional treatment. Melatonin was administered enterally in two doses of 10 mg each, 1 h apart. TNF-α levels were measured in all patients 72 h posttreatment. CT group experienced extended hospital stay, longer feeding discontinuation, delayed full enteral intake, higher NEC incidence, increased mortality, and higher TNF-α compared with the MT group (P = .032, <.001, <.001, <.001, .03, and <.001, respectively). Enteral melatonin significantly reduced NEC incidence and mortality, accelerated achievement of full enteral feeding, and lowered TNF-α levels in preterm neonates with FI. It demonstrates a practical, affordable, orally administered therapy that is accessible and reproducible in low-resource settings, addressing the burden of NEC in preterm infants where it is critically needed.